The MPP is a public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for twelve antiretrovirals, two hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our licence page.

MPP in Numbers

9 patent holders with MPP signed agreements
12.9 million patient-years through MPP’s generic partners
20 generic manufacturers and product developers sublicensed from the MPP
16 products licensed to the MPP
120+ ongoing pharmaceutical development projects
87% to 91%
87% to 91% of people living with HIV in developing countries covered by the MPP adult licences
92 to 131
92 to 131 countries covered by MPP adults licences
312 million dollars saved, from 2012 to December 2016

KPMG calculated savings of $312 million and supply of 12.9 million patient-years of treatments through the MPP’s generic partners.

Access the report.

This website uses cookies to ensure you get the best experience on our website. Learn More